Bisphosphonates Reduce Bone Toughness Over Time
Abaloparatide vs. Alendronate for Osteoporosis
Denosumab Dosing Delays Tied to Increased Fracture Risk
Bone Density Concerns: Guidance on Tackling Fracture Risk in CKD
Zoledronate After Denosumab Does Not Fully Prevent Bone Loss
After Hip Fracture, Earlier Osteoporosis Drug Initiation Tied to Lower Subsequent Fracture Risk
High-Dose Teriparatide with Denosumab Gives Bigger BMD Boost
Osteoporosis Drugs Don’t Reduce Overall Mortality
U.S. Supreme Court Tosses Ruling Against Merck on Fosamax Osteoporosis Drug
- 1
- 2
- 3
- 4
- Next Page »